Vertex posts positive data from cystic fibrosis triple combo trials

Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients of cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.